Dr. Yi Ren is Head of CMC at Roche Pharma Research and Early Development (pRED) Center in Shanghai, China. pRED China is a fully owned subsidiary of Roche Holding, which is dedicated to innovative medical research and development in drug discovery. Dr. Ren received his Ph.D. degree in Organic Chemistry from the University of Toronto. He completed his post-doctoral training at the University of Michigan. Dr. Ren holds an MBA degree from Rutgers University.
Dr. Ren has worked in the field of CMC for more than 13 years. As a Research Leader at Roche Nutley research center, he led the chemical synthesis efforts for more than twenty programs among which more than ten programs entered into clinical development. He is a co-inventor of Zelboraf for the treatment of melanoma which is the deadliest form of skin cancer. Upon returning to China in 2008, Dr. Ren is in charge of CMC operations at Roche R&D China. In addition to building up the team and facilities, and overseeing internal CMC operations, Dr. Ren is also responsible for establishing and maintaining broad scientific and business collaborations with external CROs/CMOs and academic institutions in CMC areas. Dr. Ren is very experienced in the overall drug research and development processes.